Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Goodwill (2017 - 2025)

Historic Goodwill for Avalo Therapeutics (AVTX) over the last 9 years, with Q3 2025 value amounting to $10.5 million.

  • Avalo Therapeutics' Goodwill changed 0.0% to $10.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.5 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $10.5 million for FY2024, which is 0.0% changed from last year.
  • Latest data reveals that Avalo Therapeutics reported Goodwill of $10.5 million as of Q3 2025, which was down 0.0% from $10.5 million recorded in Q2 2025.
  • Over the past 5 years, Avalo Therapeutics' Goodwill peaked at $14.4 million during Q1 2021, and registered a low of $10.5 million during Q4 2023.
  • In the last 5 years, Avalo Therapeutics' Goodwill had a median value of $14.4 million in 2021 and averaged $12.8 million.
  • Its Goodwill has fluctuated over the past 5 years, first changed by 0.0% in 2021, then tumbled by 2711.5% in 2023.
  • Quarter analysis of 5 years shows Avalo Therapeutics' Goodwill stood at $14.4 million in 2021, then changed by 0.0% to $14.4 million in 2022, then decreased by 27.11% to $10.5 million in 2023, then changed by 0.0% to $10.5 million in 2024, then changed by 0.0% to $10.5 million in 2025.
  • Its Goodwill stands at $10.5 million for Q3 2025, versus $10.5 million for Q2 2025 and $10.5 million for Q1 2025.